|
|
2F52 |
|
Vaxjo ID |
117 |
|
Vaccine Adjuvant Name |
2F52 |
|
Adjuvant VO ID |
VO_0005303
|
|
Description |
small molecule with unknown receptor that correlates to dentritic cells (adjuvant binds to receptor on cell); induces Th1/Th2 immune responses; strong adjuvant when used with influenza vaccine |
|
Stage of Development |
Research |
|
Location Licensed |
US (UCSD) |
|
Host Species for Testing |
Mouse |
|
Components |
adjuvant is formulated with 0.1% DMSO; type I IFN receptor (adjuvant receptor) is made of two subunits, IFNAR1 and IFNAR2 --> associated with the Janus activated kinases; small-molecular-weight compound that prolongs type I IFN signaling would function as a co-adjuvant in vaccines |
|
Storage |
Solid form is stable at 4C for > 1 years |
|
Function |
Type: synthetic vaccine adjuvant. Induces Th1/Th2 mixed immune profile. innate immune activation |
| Related Vaccine(s) |
|
| References |
(Carson, 2021): Vaccine Adjuvant Compendium (VAC) [https://vac.niaid.nih.gov/view?id=8]
Shukla et al., 2018: Shukla NM, Arimoto KI, Yao S, Fan JB, Zhang Y, Sato-Kaneko F, Lao FS, Hosoya T, Messer K, Pu M, Cottam HB, Carson DA, Hayashi T, Zhang DE, Corr M. Identification of Compounds That Prolong Type I Interferon Signaling as Potential Vaccine Adjuvants. SLAS discovery : advancing life sciences R & D. 2018; 23(9); 960-973. [PubMed: 29751735].
|
|
